arrow
S

Saul J. Priceman

city of hope
H指数:34
被引数:8,788

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform

个性化SNAP™-TIL(特异性新抗原肽-TIL)治疗平台的临床前概念验证

2026-07-050
OA
Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

全蛋白质筛选和多模态分析抗原特异性CD4+ T细胞在单细胞分辨率

2026-05-120
OAAI
CTIM-07. A PHASE 1 STUDY OF INTRAVENTRICULARLY ADMINISTERED AUTOLOGOUS HER2-TARGETING CHIMERIC ANTIGEN RECEPTOR T CELLS (HER2-CAR T CELLS), WITH AND WITHOUT LYMPHODEPLETION, IN HER2-POSITIVE BREAST CANCER PATIENTS WITH RECURRENT BRAIN AND/OR LEPTOMENINGEAL METASTASES

CTIM-07。一项I期研究,评估经脑室内给药的自体HER2靶向嵌合抗原受体T细胞(HER2-CAR T细胞),在伴或不伴淋巴细胞清除的情况下,用于HER2阳性乳腺癌患者复发脑和/或软脑膜转移的疗效。

2025-11-110
OA
Collagen-binding IL-12-armoured STEAP1 CAR-T cells reduce toxicity and treat prostate cancer in mouse models

胶原蛋白结合IL-12装甲STEAP1 CAR-T细胞可降低毒性并治疗小鼠模型中的前列腺癌

2025-10-230
OAAI
Intracranial metastases from solid tumors: Call to action and consensus from the Society for Neuro-Oncology and American Society of Clinical Oncology collaborative

颅内转移瘤:神经肿瘤学会和临床肿瘤学会协作的呼吁与共识

2025-10-060
OAAI
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery

靶向PD-L1的融合蛋白工程化改造的实体瘤CAR-T细胞,用于局部IL-12递送

2025-10-010
OAAI
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
2024-06-1215
OAAI
Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors
2024-05-021
PRE
Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

CAR T细胞中的抗原依赖性IL-12信号传导促进区域至全身性疾病靶向

2023-08-0723
OAAI